Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences

Gilead Sciences K.K. said on March 26 that it received regulatory approval on the same day for its oral chronic hepatitis C virus (HCV) infection treatment Sovaldi Tablets 400 mg (sofosbuvir) in Japan. This is the first product to be...read more